Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jan 21

PMID 36674430

Authors

Francesco Lasorsa

Nicola Antonio di Meo

Monica Rutigliano

Matteo Ferro

Daniela Terracciano

Octavian Sabin Tataru

Michele Battaglia

Pasquale Ditonno

Giuseppe Lucarelli

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is the most common male malignancy and the fifth leading cause of cancer death in men worldwide. Prostate cancer cells are characterized by a hybrid glycolytic/oxidative phosphorylation phenotype determined by androgen receptor signaling. An increased lipogenesis and cholesterogenesis have been described in PCa cells. Many studies have shown that enzymes involved in these pathways are overexpressed in PCa. Glutamine becomes an essential amino acid for PCa cells, and its metabolism is thought to become an attractive therapeutic target. A crosstalk between cancer and stromal cells occurs in the tumor microenvironment because of the release of different cytokines and growth factors and due to changes in the extracellular matrix. A deeper insight into the metabolic changes may be obtained by a multi-omic approach integrating genomics, transcriptomics, metabolomics, lipidomics, and radiomics data.

Citing Articles

Survival outcome prediction of esophageal squamous cell carcinoma patients based on radiomics and mutation signature.

Yan T, Yan Z, Chen G, Xu S, Wu C, Zhou Q Cancer Imaging. 2025; 25(1):9.

PMID: 39891186 PMC: 11783911. DOI: 10.1186/s40644-024-00821-5.

Downregulated Regucalcin Expression Induces a Cancer-like Phenotype in Non-Neoplastic Prostate Cells and Augments the Aggressiveness of Prostate Cancer Cells: Interplay with the G Protein-Coupled Oestrogen Receptor?.

Fonseca L, Carreira R, Feijo M, Cavaco J, Cardoso H, Vaz C Cancers (Basel). 2024; 16(23).

PMID: 39682121 PMC: 11640704. DOI: 10.3390/cancers16233932.

Insights into Metabolic Reprogramming in Tumor Evolution and Therapy.

Chiu C, Guerrero J, Regalado R, Zhou J, Zamora M, Notarte K Cancers (Basel). 2024; 16(20).

PMID: 39456607 PMC: 11506062. DOI: 10.3390/cancers16203513.

Altered metabolism in cancer: insights into energy pathways and therapeutic targets.

Tufail M, Jiang C, Li N Mol Cancer. 2024; 23(1):203.

PMID: 39294640 PMC: 11409553. DOI: 10.1186/s12943-024-02119-3.

Identification of prostate cancer bone metastasis related genes and potential therapy targets by bioinformatics and in vitro experiments.

Jiang H, Liu M, Deng Y, Zhang C, Dai L, Zhu B J Cell Mol Med. 2024; 28(15):e18511.

PMID: 39098992 PMC: 11298316. DOI: 10.1111/jcmm.18511.

References

Spratlin J, Serkova N, Eckhardt S . Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009; 15(2):431-40. PMC: 2676437. DOI: 10.1158/1078-0432.CCR-08-1059. View

Fedeles B, Singh V, Delaney J, Li D, Essigmann J . The AlkB Family of Fe(II)/α-Ketoglutarate-dependent Dioxygenases: Repairing Nucleic Acid Alkylation Damage and Beyond. J Biol Chem. 2015; 290(34):20734-20742. PMC: 4543635. DOI: 10.1074/jbc.R115.656462. View

Costello L, Franklin R . Zinc is decreased in prostate cancer: an established relationship of prostate cancer!. J Biol Inorg Chem. 2010; 16(1):3-8. PMC: 3735606. DOI: 10.1007/s00775-010-0736-9. View

Altuna-Coy A, Ruiz-Plazas X, Sanchez-Martin S, Ascaso-Til H, Prados-Saavedra M, Alves-Santiago M . The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell's metabolic crosstalk. BMC Med. 2022; 20(1):255. PMC: 9386931. DOI: 10.1186/s12916-022-02457-3. View

Asim M, Massie C, Orafidiya F, Pertega-Gomes N, Warren A, Esmaeili M . Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2015; 108(5). PMC: 4849803. DOI: 10.1093/jnci/djv371. View

Kolenko V, Teper E, Kutikov A, Uzzo R . Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol. 2013; 10(4):219-26. PMC: 3702371. DOI: 10.1038/nrurol.2013.43. View

Song Y, Shiota M, Kuroiwa K, Naito S, Oda Y . The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol. 2011; 24(9):1272-80. DOI: 10.1038/modpathol.2011.76. View

Vavallo A, Simone S, Lucarelli G, Rutigliano M, Galleggiante V, Grandaliano G . Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore). 2014; 93(27):e183. PMC: 4602816. DOI: 10.1097/MD.0000000000000183. View

Swanson M, Keshari K, Tabatabai Z, Simko J, Shinohara K, Carroll P . Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008; 60(1):33-40. PMC: 2643975. DOI: 10.1002/mrm.21647. View

10.

Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J . Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4):222-234. PMC: 7472658. DOI: 10.1038/nrurol.2018.9. View

11.

Ros S, Santos C, Moco S, Baenke F, Kelly G, Howell M . Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012; 2(4):328-43. DOI: 10.1158/2159-8290.CD-11-0234. View

12.

Murtola T, Syvala H, Pennanen P, Blauer M, Solakivi T, Ylikomi T . The importance of LDL and cholesterol metabolism for prostate epithelial cell growth. PLoS One. 2012; 7(6):e39445. PMC: 3384647. DOI: 10.1371/journal.pone.0039445. View

13.

Shemshaki G, Niranjana Murthy A, Malini S . Assessment and Establishment of Correlation between Reactive Oxidation Species, Citric Acid, and Fructose Level in Infertile Male Individuals: A Machine-Learning Approach. J Hum Reprod Sci. 2021; 14(2):129-136. PMC: 8279050. DOI: 10.4103/jhrs.jhrs_26_21. View

14.

Gaither L, Eide D . The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells. J Biol Chem. 2001; 276(25):22258-64. DOI: 10.1074/jbc.M101772200. View

15.

Han C, Schoene N, Lei K . Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells. Am J Physiol Cell Physiol. 2009; 297(5):C1188-99. DOI: 10.1152/ajpcell.00042.2009. View

16.

Moon J, Jin W, Kwak J, Kim H, Yun M, Kim J . Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J. 2010; 433(1):225-33. DOI: 10.1042/BJ20101104. View

17.

Kochuparambil S, Al-Husein B, Goc A, Soliman S, Somanath P . Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2010; 336(2):496-505. DOI: 10.1124/jpet.110.174870. View

18.

Calgani A, Delle Monache S, Cesare P, Vicentini C, Bologna M, Angelucci A . Leptin contributes to long-term stabilization of HIF-1α in cancer cells subjected to oxygen limiting conditions. Cancer Lett. 2016; 376(1):1-9. DOI: 10.1016/j.canlet.2016.03.027. View

19.

Stewart C, Stuart L, Wilkinson K, van Gils J, Deng J, Halle A . CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2009; 11(2):155-61. PMC: 2809046. DOI: 10.1038/ni.1836. View

20.

Watt M, Clark A, Selth L, Haynes V, Lister N, Rebello R . Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019; 11(478). DOI: 10.1126/scitranslmed.aau5758. View